Sakar Healthcare posts Rs 11 cr profit in Q2

The company said the second quarter growth was supported by new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage, and disciplined cost management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/atrA53o
via IFTTT

Read More

Mankind Pharma shares key business developments from Q2 & H1 of FY27

The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of 18.7% and 15.8%, respectively. In acute therapies, gastroenterology grew at 1.3 times the market rate, while vitamins, minerals and nutrients (VMN) expanded at 1.4 times that rate.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8DIvUoX
via IFTTT

Read More

Lord’s Mark Industries Limited becomes Asia’s first company to secure multiple US FDA registrations for 200+ surgical and hygiene products; US exports to begin in December

Silvassa manufacturing expansion completed ahead of schedule as the company prepares to expand its international footprint across the United States and South America

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z25eqPc
via IFTTT

Read More

Dr Reddy's bets on generic semaglutide, biosimilars

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3y6PozZ
via IFTTT

Read More

Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?

Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% rise in prescriptions over six months. Prices have fallen from over Rs 1 lakh to around Rs 30,000 per cycle, but hospital stocking practices could determine whether patients benefit from lower costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RCM4mj0
via IFTTT

Read More

One Science Nutrition: Building a science-led approach to sports nutrition

One Science Nutrition was co-founded by Aman and Aniket Vachher to create credible sports nutrition products. The brand aims to cater to evolving consumer expectations around product quality and transparency. Their product range includes various supplements that support diverse fitness goals and health benefits. Future strategies involve leveraging artificial intelligence to enhance consumer experiences and product discovery. The founders emphasize maintaining core values while pursuing growth in the nutrition industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/90xr2IG
via IFTTT

Read More

Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial

Johnson & Johnson reported results from an early-stage trial of their prostate cancer drug JNJ-6143. The trial involved patients with advanced prostate cancer who had undergone multiple treatments. Results showed 77% of patients experienced a significant drop in PSA levels after treatment. Additionally, 69% of patients demonstrated confirmed partial or complete tumor response through imaging. Common side effects included nausea and elevated cholesterol levels, with one patient discontinuing treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GY9MseC
via IFTTT

Read More